GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

GSK said it is hold­ing steady in the face of on­go­ing reg­u­la­to­ry and po­ten­tial po­lit­i­cal pres­sures on its vac­cines fran­chise, which saw full-year 2024 sales …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER